MET targeting: time for a rematch
JP Koch, DM Aebersold, Y Zimmer, M Medová - Oncogene, 2020 - nature.com
MET, the receptor tyrosine kinase (RTK) for hepatocyte growth factor, is a proto-oncogene
involved in embryonic development and throughout life in homeostasis and tissue …
involved in embryonic development and throughout life in homeostasis and tissue …
Mesenchymal epithelial transition (MET): a key player in chemotherapy resistance and an emerging target for potentiating cancer immunotherapy
KKW To, W Cho - Current Cancer Drug Targets, 2022 - ingentaconnect.com
The MET protein is a cell surface receptor tyrosine kinase predominately expressed in
epithelial cells. Upon binding of its only known ligand, hepatocyte growth factor (HGF), MET …
epithelial cells. Upon binding of its only known ligand, hepatocyte growth factor (HGF), MET …
[HTML][HTML] Silencing of LOC389641 impairs cell proliferation and induces autophagy via EGFR/MET signaling in lung adenocarcinoma
L Xiao, Y Li, X Zeng, Z Zhou, S Hu, S Zhang… - Aging (Albany …, 2021 - ncbi.nlm.nih.gov
High-throughput RNA-sequencing studies of tumor samples have identified a large number
of long non-coding RNAs (lncRNAs) which are associated with various types of cancer …
of long non-coding RNAs (lncRNAs) which are associated with various types of cancer …
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
D Sakai, HC Chung, DY Oh, SH Park… - Cancer chemotherapy …, 2017 - Springer
Purpose Mesenchymal–epithelial transition factor (MET) is expressed in gastric cancer and
associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics …
associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics …
Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes
MB Kelley, TJ Geddes, M Ochiai, NM Lampl… - Plos one, 2022 - journals.plos.org
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin
cancer in the United States, affecting one million people per year. Patients with aggressive …
cancer in the United States, affecting one million people per year. Patients with aggressive …
Generation of Anti-Tumorigenic Met Receptor Variants by Splicing Interference
T Rathod - 2019 - search.proquest.com
Aberrant activation of MET, a receptor tyrosine kinase (RTK), leads to tumor growth, invasion
and metastasis and is implicated in multiple types of cancers. Hence, various strategies …
and metastasis and is implicated in multiple types of cancers. Hence, various strategies …